SingleComments Off on A Decision for Life – Treatment decisions in newly diagnosed families with spinal muscular atrophy (SMA)
European neuromuscular experts presented eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring, in order to aid the rational use of Zolgensma™ for the treatment of SMA (Kirschner, et al., 2020). In response to this consensus statement, a group of patient representatives from SMA Europe highlight considerations that must be taken into account when considering treatment.
Authors: N. Gusset, Y. Erbas, O. Germanenko, K. Rucinski, E. Stumpe and M. de Lemus.
Journal: Neuromuscular Disorders